Human pluripotent stem cells for modelling human liver diseases and cell therapy

Current Gene Therapy

Volumn 13, Issue 2, 2013, Pages 120-132

  Dianat, Noushin ^a,b   Steichen, Clara ^a,b   Vallier, Ludovic ^c   Weber, Anne ^a,b   Dubart Kupperschmitt, Anne ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Disease modelling; Hepatocyte differentiation; Induced pluripotent stem cells; Liver diseases; Regenerative medicine

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CONNEXIN 32; CYTOCHROME P450 3A4; CYTOCHROME P450 3A7; IMMUNOSUPPRESSIVE AGENT; LIVER ENZYME; MICRORNA 122; NEUROGENIN 3; STAGE SPECIFIC EMBRYO ANTIGEN 1; TELOMERASE; TRANSCRIPTION FACTOR MAFA; TRANSCRIPTION FACTOR PDX 1;

BRAIN SPONGIOSIS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL INTERACTION; CELL THERAPY; CELL TRANSPLANTATION; CRYOPRESERVATION; DNA METHYLATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENE THERAPY; HEMOPHILIA B; HUMAN; IMMUNE SYSTEM; IN VIVO STUDY; LIVER CELL; LIVER DEVELOPMENT; LIVER DISEASE; LIVER TRANSPLANTATION; LOBECTOMY; MESENCHYMAL STEM CELL; METABOLIC DISORDER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; REVIEW; SURVIVAL RATE; TARGETED GENE REPAIR; VIRUS ENTRY;

CELL DIFFERENTIATION; DRUG DISCOVERY; EMBRYONIC STEM CELLS; HEPATOCYTES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIVER; LIVER FAILURE, ACUTE; LIVER REGENERATION; METABOLIC DISEASES; TISSUE THERAPY;

EID: 84876696226     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523211313020006     Document Type: Review

References (131)

1. Dhawan A, Puppi J, Hughes RD, Mitry RR. Human hepatocyte transplantation: current experience and future challenges. Nat Rev Gastroenterol Hepatol 2010; 7:288-298.
2. Ribes-Koninckx C, Ibars EP, Agrasot MA, et al. Clinical outcome of hepatocyte transplantation in four pediatric patients with inherited metabolic diseases. Cell Transplant 2012; 21:2267-2282.
3. Kawahara T, Toso C, Douglas DN, et al. Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model. Liver Transpl 2010; 16:974-982.
4. Hughes RD, Mitry RR, Dhawan A. Current status of hepatocyte transplantation. Transplantation 2012; 93:342-347.
5. Puppi J, Strom SC, Hughes RD, et al. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. Cell Transplant 2012; 21:1-10.
6. Terry C, Dhawan A, Mitry RR, et al. Optimization of the cryopreservation and thawing protocol for human hepatocytes for use in cell transplantation. Liver Transpl 2010; 16:229-237.
7. Najimi M, Smets F, Sokal E. Hepatocyte apoptosis. Methods Mol Biol 2009; 481:59-74.
8. Antherieu S, Chesne C, Li R, et al. Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol In Vitro 2012; 26:1278-1285.
9. Popp FC, Slowik P, Eggenhofer E, et al. No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells 2007; 25:639-645.
10. Kuo TK, Hung SP, Chuang CH, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 2008; 134:2111-2121, 2121 e1-3.
11. Tsai PC, Fu TW, Chen YM, et al. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. Liver Transpl 2009; 15:484-495.
12. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev 2003; 120:117-130.
13. Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis 2003; 23:385-396.
14. Schmelzer E, Zhang L, Bruce A, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007; 204:1973-1987.
15. Zhang C, Guo X, Jiang G, et al. CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma. Int J Cancer 2008; 123:998-1004.
16. Schmelzer E, Reid LM. Human telomerase activity, telomerase and telomeric template expression in hepatic stem cells and in livers from fetal and postnatal donors. Eur J Gastroenterol Hepatol 2009; 21:1191-1198.
17. Turner R, Lozoya O, Wang Y, et al. Human hepatic stem cell and maturational liver lineage biology. Hepatology 2011; 53:1035-1045.
18. Lemaigre F. [Lineage fate decisions in normal and regenerating liver]. Med Sci (Paris) 2012; 28:958-962.
19. Mahieu-Caputo D, Allain JE, Branger J, et al. Repopulation of athymic mouse liver by cryopreserved early human fetal hepatoblasts. Hum Gene Ther 2004; 15:1219-1228.
20. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145-1147.
21. Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012; 379:713-720.
22. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872.
23. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451:141-146.
24. Maehr R, Chen S, Snitow M, et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A 2009; 106:15768-15773.
25. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009; 136:964-977.
26. Yoshida T, Takayama K, Kondoh M, et al. Use of human hepatocyte- like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection. Biochem Biophys Res Commun 2011; 416:119-124.
27. Roelandt P, Obeid S, Paeshuyse J, et al. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J Hepatol 2012; 57:246-251.
28. Schwartz RE, Trehan K, Andrus L, et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A 2012; 109:2544-2548.
29. Tao W, Xu C, Ding Q, et al. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. Virology 2009; 395:67-76.
30. Martin U, Winkler ME, Id M, et al. Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV). Xenotransplantation 2000; 7:138-142.
31. Nibourg GA, Chamuleau RA, van Gulik TM, Hoekstra R. Proliferative human cell sources applied as biocomponent in bioartificial livers: a review. Expert Opin Biol Ther 2012; 12:905-921.
32. Zhang S, Chen S, Li W, et al. Rescue of ATP7B function in hepatocyte- like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum Mol Genet 2011; 20:3176-3187.
33. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318:1920-1923.
34. Lavon N, Yanuka O, Benvenisty N. Differentiation and isolation of hepatic-like cells from human embryonic stem cells. Differentiation 2004; 72:230-238.
35. Schwartz RE, Linehan JL, Painschab MS, et al. Defined conditions for development of functional hepatic cells from human embryonic stem cells. Stem Cells Dev 2005; 14:643-655.
36. Duan Y, Catana A, Meng Y, et al. Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells in vitro and in vivo. Stem Cells 2007; 25:3058-3068.
37. Cai J, Zhao Y, Liu Y, et al. Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 2007; 45:1229-1239.
38. Soto-Gutierrez A, Navarro-Alvarez N, Zhao D, et al. Differentiation of mouse embryonic stem cells to hepatocyte-like cells by coculture with human liver nonparenchymal cell lines. Nat Protoc 2007; 2:347-356.
39. Hay DC, Fletcher J, Payne C, et al. Highly efficient differentiation of hESCs to functional hepatic endoderm requires Activin A and Wnt3a signaling. Proc Natl Acad Sci U S A 2008; 105:12301-12306.
40. Basma H, Soto-Gutierrez A, Yannam GR, et al. Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology 2009; 136:990-999.
41. Brolen G, Sivertsson L, Bjorquist P, et al. Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. J Biotechnol 2010; 145:284-294.
42. Si-Tayeb K, Noto FK, Nagaoka M, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010; 51:297-305.
43. Martin MJ, Muotri A, Gage F, Varki A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 2005; 11:228-232.
44. Wu MY, Hill CS. Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell 2009; 16:329-343.
45. Vallier L, Touboul T, Brown S, et al. Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells. Stem Cells 2009; 27:2655-2666.
46. Brown S, Teo A, Pauklin S, et al. Activin/Nodal signaling controls divergent transcriptional networks in human embryonic stem cells and in endoderm progenitors. Stem Cells 2011; 29:1176-1185.
47. Teo AK, Arnold SJ, Trotter MW, et al. Pluripotency factors regulate definitive endoderm specification through eomesodermin. Genes Dev 2011; 25:238-250.
48. Singh AM, Reynolds D, Cliff T, et al. Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 2012; 10:312-326.
49. McLean AB, D'Amour KA, Jones KL, et al. Activin a efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells 2007; 25:29-38.
50. Lemaigre F, Zaret KS. Liver development update: new embryo models, cell lineage control, and morphogenesis. Curr Opin Genet Dev 2004; 14:582-590.
51. Si-Tayeb K, Lemaigre FP, Duncan SA. Organogenesis and development of the liver. Dev Cell 2010; 18:175-189.
52. Suzuki A, Zheng YW, Kaneko S, et al. Clonal identification and characterization of self-renewing pluripotent stem cells in the developing liver. J Cell Biol 2002; 156:173-184.
53. Dan YY, Riehle KJ, Lazaro C, et al. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A 2006; 103:9912-9917.
54. Malhi H, Irani AN, Gagandeep S, Gupta S. Isolation of human progenitor liver epithelial cells with extensive replication capacity and differentiation into mature hepatocytes. J Cell Sci 2002; 115:2679-2688.
55. Allain JE, Dagher I, Mahieu-Caputo D, et al. Immortalization of a primate bipotent epithelial liver stem cell. Proc Natl Acad Sci U S A 2002; 99:3639-3644.
56. Delgado JP, Vanneaux V, Branger J, et al. The role of HGF on invasive properties and repopulation potential of human fetal hepatic progenitor cells. Exp Cell Res 2009; 315:3396-3405.
57. Touboul T, Hannan NR, Corbineau S, et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 2010; 51:1754-1765.
58. Hu BY, Weick JP, Yu J, et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A 2010; 107:4335-4340.
59. Kajiwara M, Aoi T, Okita K, et al. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A 2012; 109:12538-12543.
60. Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotechnol 2008; 26:120-126.
61. Flaim CJ, Chien S, Bhatia SN. An extracellular matrix microarray for probing cellular differentiation. Nat Methods 2005; 2:119-125.
62. Wang Y, Yao HL, Cui CB, et al. Paracrine signals from mesenchymal cell populations govern the expansion and differentiation of human hepatic stem cells to adult liver fates. Hepatology 2010; 52:1443-1454.
63. Hay DC, Pernagallo S, Diaz-Mochon JJ, et al. Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism. Stem Cell Res 2011; 6:92-102.
64. Weber A, Groyer-Picard MT, Franco D, Dagher I. Hepatocyte transplantation in animal models. Liver Transpl 2009; 15:7-14.
65. Rhim JA, Sandgren EP, Palmiter RD, Brinster RL. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc Natl Acad Sci U S A 1995; 92:4942-4946.
66. Meuleman P, Libbrecht L, De Vos R, et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005; 41:847-856.
67. Payne CM, Samuel K, Pryde A, et al. Persistence of functional hepatocyte-like cells in immune-compromised mice. Liver Int 2011; 31:254-262.
68. Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010; 120:3127-3136.
69. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007; 25:903-910.
70. Vaughan AM, Mikolajczak SA, Wilson EM, et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest 2012; 122:3618-3628.
71. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134:877-886.
72. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321:1218-1221.
73. Ebert AD, Yu J, Rose FF, Jr., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457:277-280.
74. Grskovic M, Javaherian A, Strulovici B, Daley GQ. Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov 2011; 10:915-929.
75. Tiscornia G, Vivas EL, Izpisua Belmonte JC. Diseases in a dish: modeling human genetic disorders using induced pluripotent cells. Nat Med 2011; 17:1570-1576.
76. Trounson A, Shepard KA, DeWitt ND. Human disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev 2012; 22:509-516.
77. Perrier A, Peschanski M. How can human pluripotent stem cells help decipher and cure Huntington's disease? Cell Stem Cell 2012; 11:153-161.
78. Seibler P, Graziotto J, Jeong H, et al. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci 2011; 31:5970-5976.
79. Egawa N, Kitaoka S, Tsukita K, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012; 4:145-4104.
80. Brown MS, Goldstein JL. Biomedicine. Lowering LDL--not only how low, but how long? Science 2006; 311:1721-1723.
81. Bruckert E. New lipid-modifying therapies. Expert Opin Investig Drugs 2003; 12:325-335.
82. Hudgins LC, Kleinman B, Scheuer A, et al. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102:1199-1204.
83. Huijgen R, Kindt I, Verhoeven SB, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol- lowering treatment but a minority reaches treatment goal. PLoS One 2010; 5:e9220.
84. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1:1148-1154.
85. Petrus I, Chuah M, VandenDriessche T. Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med 2010; 12:797-809.
86. Wu YM, Kao CY, Huang YJ, et al. Genetic modification of donor hepatocytes improves therapeutic efficacy for hemophilia B in mice. Cell Transplant 2010; 19:1169-1180.
87. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365:2357-2365.
88. Kasuda S, Tatsumi K, Sakurai Y, et al. Expression of coagulation factors from murine induced pluripotent stem cell-derived liver cells. Blood Coagul Fibrinolysis 2011; 22:271-279.
89. Cao J, Shang CZ, Lu LH, et al. Differentiation of embryonic stem cells into hepatocytes that coexpress coagulation factors VIII and IX. Acta Pharmacol Sin 2010; 31:1478-1486.
90. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357:605-607.
91. Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in alpha1-antitrypsin deficiency: molecular and cellular insights. Eur Respir J 2009; 34:475-488.
92. Griesenbach U, Geddes DM, Alton EW. Advances in cystic fibrosis gene therapy. Curr Opin Pulm Med 2004; 10:542-546.
93. Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation 2006; 82:441-449.
94. Nguyen TH, Birraux J, Wildhaber B, et al. Ex vivo lentivirus transduction and immediate transplantation of uncultured hepatocytes for treating hyperbilirubinemic Gunn rat. Transplantation 2006; 82:794-803.
95. Nguyen TH, Mainot S, Lainas P, et al. Ex vivo liver-directed gene therapy for the treatment of metabolic diseases: advances in hepatocyte transplantation and retroviral vectors. Curr Gene Ther 2009; 9:136-149.
96. Birraux J, Menzel O, Wildhaber B, et al. A step toward liver gene therapy: efficient correction of the genetic defect of hepatocytes isolated from a patient with Crigler-Najjar syndrome type 1 with lentiviral vectors. Transplantation 2009; 87:1006-1012.
97. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118:3132-3142.
98. Connelly S. Adenoviral vectors for liver-directed gene therapy. Curr Opin Mol Ther 1999; 1:565-572.
99. Howden SE, Gore A, Li Z, et al. Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. Proc Natl Acad Sci U S A 2011; 108:6537-6542.
100. Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011; 475:217-221.
101. Liu GH, Suzuki K, Qu J, et al. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 2011; 8:688-694.
102. Vallier L, Alexander M, Pedersen R. Conditional gene expression in human embryonic stem cells. Stem Cells 2007; 25:1490-1497.
103. Urnov FD, Rebar EJ, Holmes MC, et al. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010; 11:636-646.
104. Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011; 29:731-734.
105. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011; 478:391-394.
106. Gupta A, Meng X, Zhu LJ, et al. Zinc finger protein-dependent and -independent contributions to the in vivo off-target activity of zinc finger nucleases. Nucleic Acids Res 2011; 39:381-392.
107. Vons C, Beaudoin S, Helmy N, et al. First description of the surgical anatomy of the cynomolgus monkey liver. Am J Primatol 2009; 71:400-408.
108. Liu H, Zhu F, Yong J, et al. Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell 2008; 3:587-590.
109. Okahara-Narita J, Umeda R, Nakamura S, et al. Induction of pluripotent stem cells from fetal and adult cynomolgus monkey fibroblasts using four human transcription factors. Primates 2012; 53:205-213.
110. Wu Y, Mishra A, Qiu Z, et al. Nonhuman primate induced pluripotent stem cells in regenerative medicine. Stem Cells Int 2012; 2012:767195.
111. Blin G, Nury D, Stefanovic S, et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 2010; 120:1125-1139.
112. Joseph B, Malhi H, Bhargava KK, et al. Kupffer cells participate in early clearance of syngeneic hepatocytes transplanted in the rat liver. Gastroenterology 2002; 123:1677-1685.
113. Dagher I, Boudechiche L, Branger J, et al. Efficient hepatocyte engraftment in a nonhuman primate model after partial portal vein embolization. Transplantation 2006; 82:1067-1073.
114. Lainas P, Boudechiche L, Osorio A, et al. Liver regeneration and recanalization time course following reversible portal vein embolization. J Hepatol 2008; 49:354-362.
115. Dagher I, Nguyen TH, Groyer-Picard MT, et al. Efficient hepatocyte engraftment and long-term transgene expression after reversible portal embolization in nonhuman primates. Hepatology 2009; 49:950-959.
116. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471:68-73.
117. Mekhoubad S, Bock C, de Boer AS, et al. Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 2012; 10:595-609.
118. Ohi Y, Qin H, Hong C, et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol 2011; 13:541-549.
119. Ruiz S, Diep D, Gore A, et al. Identification of a specific reprogramming- associated epigenetic signature in human induced pluripotent stem cells. Proc Natl Acad Sci U S A 2012; 109:16196-16201.
120. Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010; 6:407-411.
121. Sheridan SD, Theriault KM, Reis SA, et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One 2011; 6:e26203.
122. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471:63-67.
123. Ji J, Ng SH, Sharma V, et al. Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells. Stem Cells 2012; 30:435-440.
124. Abyzov A, Mariani J, Palejev D, et al. Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature 2012; 492:438-442.
125. Nie B, Wang H, Laurent T, Ding S. Cellular reprogramming: a small molecule perspective. Curr Opin Cell Biol 2012; 24:784-792.
126. Pournasr B, Khaloughi K, Salekdeh GH, et al. Concise review: alchemy of biology: generating desired cell types from abundant and accessible cells. Stem Cells 2011; 29:1933-1941.
127. Vierbuchen T, Wernig M. Direct lineage conversions: unnatural but useful? Nat Biotechnol 2011; 29:892-907.
128. Xie H, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into macrophages. Cell 2004; 117:663-676.
129. Huang P, He Z, Ji S, et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475:386-389.
130. Sekiya S, Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 2011; 475:390-393.
131. Zhou Q, Brown J, Kanarek A, et al. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008; 455:627-632.